The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25
Open accessAbstract
The calcitonin/CGRP family of peptides includes calcitonin, α and β CGRP, amylin, adrenomedullin (AM) and adrenomedullin 2/intermedin (AM2/IMD). Their receptors consist of one of two GPCRs, the calcitonin receptor (CTR) or the calcitonin receptor‐like receptor (CLR). Further diversity arises from heterodimerization of these GPCRs with one of three receptor activity‐modifying proteins (RAMPs). This gives the CGRP receptor (CLR/RAMP1), the AM 1 and AM 2 receptors (CLR/RAMP2 or RAMP3) and the AMY 1,AMY 2 and AMY 3 receptors (CTR/RAMPs1–3 complexes, respectively). Apart from the CGRP receptor, there are only peptide antagonists widely available for these receptors, and these have limited selectivity, thus defining the function of each receptor in vivo remains challenging. Further challenges arise from the probable co‐expression of CTR with the CTR/RAMP complexes and species‐dependent splice variants of the CTR (CT(a)and CT(b)). Furthermore, the AMY 1(a)receptor is activated equally well by both amylin and CGRP, and the preferred receptor for AM2/IMD has been unclear. However, there are clear therapeutic rationales for developing agents against the various receptors for these peptides. For example, many agents targeting the CGRP system are in clinical trials, and pramlintide, an amylin analogue, is an approved therapy for insulin‐requiring diabetes. This review provides an update on the pharmacology of the calcitonin family of peptides by members of the corresponding subcommittee of the International Union of Basic and Clinical Pharmacology and colleagues.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor
McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., & Foord, S. M. (1998) · Nature · doi:10.1038/30666 · Cited by 2,134
Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
Russell, F. A., King, R., Smillie, S.-J., Kodji, X., & Brain, S. D. (2014) · Physiological Reviews · doi:10.1152/physrev.00034.2013 · Cited by 1,258
Southan, C., Sharman, J. L., Benson, H. E., Faccenda, E., Pawson, A. J., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1037 · Cited by 1,035
Poyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A., & Foord, S. M. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.233 · Cited by 804 · cited 3×
“As their names suggest, these respond to amylin (Poyner et al., 2002; Hay et al., 2015).”
BackgroundSelf-citationAdrenomedullin, a Multifunctional Regulatory Peptide*
Hinson, J. P., Kapas, S., & Smith, D. M. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0396 · Cited by 752
Amara, S. G., Arriza, J. L., Leff, S. E., Swanson, L. W., Evans, R. M., & Rosenfeld, M. G. (1985) · Science · doi:10.1126/science.2994212 · Cited by 610
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: g protein-coupled receptors
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., et al. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13878 · Cited by 588
Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486
Phase-plate cryo-EM structure of a class B GPCR–G-protein complex
Liang, Y.-L., Khoshouei, M., Radjainia, M., Zhang, Y., Glukhova, A., Tarrasch, J., Thal, D. M., Furness, S. G. B., Christopoulos, G., Coudrat, T., et al. (2017) · Nature · doi:10.1038/nature22327 · Cited by 462
Roh, J., Chang, C. L., Bhalla, A., Klein, C., & Hsu, S. Y. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305332200 · Cited by 443
Cited by
CGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Self-citationMigraine: disease characterisation, biomarkers, and precision medicine
Ashina, M., Terwindt, G. M., Al-Karagholi, M. A.-M., de Boer, I., Lee, M. J., Hay, D. L., Schulte, L. H., Hadjikhani, N., Sinclair, A. J., Ashina, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32162-0 · Cited by 381
Self-citationLong-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Biased Receptor Signaling in Drug Discovery
Kenakin, T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016790 · Cited by 294
Community guidelines for GPCR ligand bias: IUPHAR review 32
Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15811 · Cited by 232
Drug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Boccia, L., Gamakharia, S., Coester, B., Whiting, L., Lutz, T. A., & Le Foll, C. (2020) · Peptides · doi:10.1016/j.peptides.2020.170366 · Cited by 70
Lutz, T. A. (2022) · Appetite · doi:10.1016/j.appet.2022.105965 · Cited by 59
Zakariassen, H. L., John, L. M., & Lutz, T. A. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13427 · Cited by 37
Liu, Y., Chen, Q.-Y., Lee, J. H., Li, X.-H., Yu, S., & Zhuo, M. (2020) · Molecular Brain · doi:10.1186/s13041-020-00580-x · Cited by 26
Determinants of improved CGRP peptide binding kinetics revealed by enhanced molecular simulations
Kilinc, C., Babin, K. M., Pioszak, A. A., & Dickson, A. (2026) · Biophysical Journal · doi:10.1016/j.bpj.2026.03.008 · Cited by 2
Metadata
- Authors
- Hay, D. L., Garelja, M. L., Poyner, D. R., & Walker, C. S.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2017-11-28
- Volume
- 175
- Issue
- 1
- Pages
- 3-17
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2765091532
- Cited by
- 370
- References
- 107
- FWCI
- 14.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.